Zalcitabine

• Effect of weight gain on blood pressure in Ugandan persons with HIV on dolutegravir/lamivudine/ tenofovir disoproxil fumarate over 48 weeks
• HIV dynamics under multi-drug combination therapy: mathematical modelling and data fitting
• The cost-effectiveness analysis of single-tablet efavirenz-based regimen among HIV-1 infected adults in China
• Exploring the Anticancer Potential of Lamivudine-Loaded Polymeric Nanoparticles: <em>In Vitro</em> Cytotoxicity, Tissue Deposition, Biochemical Impact <em>In Vivo</em>, and Molecular Simulations Analysis
• Identification of metabolites associated with capecitabine‑induced hand‑foot syndrome using untargeted metabolomics in patients with cancer
• Evaluation of cytokine levels in HIV-infected individuals on therapy with tenofovir, lamivudine, and dolutegravir
• Two-drug regimen with dolutegravir plus lamivudine for HIV treatment in children: a narrative review
• Antiretroviral-Induced Toxicity in Umbilical Cord Blood-Derived Haematopoietic Stem/Progenitor Cells

Zalcitabine (2′-3′-dideoxycytidine, ddC), also called dideoxycytidine, is a nucleoside analog reverse-transcriptase inhibitor (NRTI) sold under the trade name Hivid. Zalcitabine was the third antiretroviral to be approved by the Food and Drug Administration (FDA) for the treatment of HIV/AIDS. It is used as part of a combination regimen.

The most common adverse events at the beginning of treatment are nausea and headache. More serious adverse events are peripheral neuropathy, which can occur in up to 33% of patients with advanced disease, oral ulcers, oesophageal ulcers, and, rarely, pancreatitis.

One of the Neuropathy associated with drugs used for Acquired immunodeficiency syndrome treatment

Zalcitabine(ddC; Hivid®): the least potent of the nucleoside analogs, therefore rarely used; dose-related neuropathy can be severe and persistent. More common in patients with DM or didanosine treatment.